Tmunity Therapeutics
Founded 2015 · CIK 0001661702 · Biotech · Acquired
Armored CAR-T cell therapies that overcome immunosuppression in solid tumors
tmunity.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $140M
- 5 Form D · Oct 2019
- 83 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 0 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $4,999,998 | |
| Private capital raised | Form D · SEC | $49,999,999 | |
| Private capital raised | Form D · SEC | $74,999,948 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2219 | KINETIQ THERAPEUTICS LLC | — | — |
| 2220 | Immuneering Corp | — | $77M |
| 2221 | Pheast Therapeutics | — | $50M |
| 2222 | Tmunity Therapeutics | — | $140M |
| 2223 | Alloy Therapeutics | — | $147M |
| 2224 | ArriVent Biopharma | — | $191M |
| 2225 | MOBIUS SCIENTIFIC INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- USMAN AZAMDirector · Executive Officer
- GRAEME BELLExecutive Officer
- Anne ChewDirector · Executive Officer
- ANNE CHEWDirector
- MICHAEL CHRISTIANOExecutive Officer
- CHRISTINA COUGHLINExecutive Officer
- PATRICK GRAYDirector
- MOJI JAMESExecutive Officer
- JASON KRENTZExecutive Officer
- JUDITH LIDirector
- Kevin MahoneyDirector
- KEVIN MAHONEYDirector
- GARRY NICHOLSONDirector
- SEAN PARKERDirector
- ALESSANDRO RIVADirector
- BETH SEIDENBERGDirector
- JIANG ZHANGDirector
- YAN ZHANGDirector
Patents
- Vector-free Process For Manufacture Of Engineered Immune Cellsapplication
- Methods For Producing Clinical-grade Lentiviral Vectorapplication
- Alternative Generation Of Allogeneic Human T Cellsapplication
- Adoptive Cell Therapy And Methods Of Dosing Thereofapplication
- Methods For Producing Clinical-grade Lentiviral Vectorapplication
- DNVSIG3 And DNVSIG8 Receptors And Methos Of Using The Sameapplication
- Adoptive Cell Therapy And Methods Of Dosing Thereofapplication
- Vector-free Process For Manufacture Of Engineered Immune Cellsapplication
- Methods For Producing Clinical-grade Lentiviral Vectorapplication
- Large Scale Car-t Immune Cell Manufacturing Method Utilizing Lentiviral Vector Transfectionapplication
- Alternative Generation Of Allogeneic Human T Cellsapplication
- Vector-free Process For Manufacture Of Engineered Immune Cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.